On the 29th August an ACE moderator answered a question about the oral anticoagulant Pradaxa.
It was stated that the drug has a licence for the prevention of deep vein thrombosis and pulmonary embolism.
This is incorrect.
Pradaxa is licenced for the prevention of stroke in people with non-valvular atrial fibrillation and the prevention of VTE (deep vein thrombosis and pulmonary embolism) in people undergoing elective hip and knee replacement surgery.
We would like to apologise for any confusion caused by this.
